Your browser is no longer supported. Please, upgrade your browser.
Gemini Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own0.10% Shs Outstand43.04M Perf Week-8.81%
Market Cap183.22M Forward P/E- EPS next Y-2.09 Insider Trans96.23% Shs Float33.31M Perf Month18.21%
Income-36.30M PEG- EPS next Q-0.45 Inst Own71.50% Short Float5.68% Perf Quarter-32.77%
Sales- P/S- EPS this Y72.70% Inst Trans-0.89% Short Ratio4.69 Perf Half Y-70.59%
Book/sh3.66 P/B1.19 EPS next Y-10.20% ROA-24.00% Target Price- Perf Year-59.22%
Cash/sh3.98 P/C1.09 EPS next 5Y- ROE-25.80% 52W Range3.22 - 19.08 Perf YTD-60.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.21% Beta-
Dividend %- Quick Ratio14.90 Sales past 5Y- Gross Margin- 52W Low35.09% ATR0.27
Employees29 Current Ratio14.90 Sales Q/Q- Oper. Margin- RSI (14)44.56 Volatility3.74% 7.36%
OptionableYes Debt/Eq0.05 EPS Q/Q- Profit Margin- Rel Volume0.24 Prev Close4.41
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume403.33K Price4.35
Recom1.20 SMA20-6.24% SMA50-0.66% SMA200-56.22% Volume96,588 Change-1.36%
Apr-08-21Initiated SVB Leerink Outperform $25
Mar-03-21Initiated Jefferies Buy $23
Mar-02-21Initiated Goldman Buy $20
Feb-16-21Initiated Stifel Buy $20
Sep-14-21 07:00AM  
Sep-10-21 08:30AM  
Sep-09-21 07:00AM  
Sep-07-21 07:00AM  
Aug-30-21 07:00AM  
Aug-12-21 07:00AM  
Aug-10-21 07:00AM  
Aug-09-21 03:10AM  
Jun-22-21 04:05PM  
May-26-21 07:00AM  
May-13-21 07:01AM  
May-09-21 05:24AM  
May-03-21 07:00AM  
May-01-21 07:00AM  
Apr-13-21 08:00AM  
Apr-12-21 08:00AM  
Mar-29-21 04:30PM  
Feb-19-21 07:00AM  
Feb-10-21 07:00AM  
Feb-09-21 07:00AM  
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Piekos BrianChief Financial OfficerMay 14Buy9.467,65572,4327,655May 18 04:45 PM
Meyenburg Jason PatrickPresident & CEOMay 14Buy9.4613,000122,92913,000May 18 04:45 PM